Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $8.27 USD
Change Today -1.03 / -11.08%
Volume 100.0
As of 9:59 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

medigene ag (MDGEF) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/15 - $16.00
52 Week Low
10/20/14 - $4.42
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDIGENE AG (MDGEF)

Related News

No related news articles were found.

medigene ag (MDGEF) Related Businessweek News

No Related Businessweek News Found

medigene ag (MDGEF) Details

Medigene AG, a biopharmaceutical company, researches and develops drugs to treat cancer and autoimmune diseases in Europe, Asia, and the United States. The company operates in two segments, Marketed Products and Drug Candidates. The Marketed Products segment offers Veregen, an ointment used to treat external genital warts. The Drug Candidates segment’s pipeline products include EndoTAG-1, a drug candidate that has completed two Phase II clinical trials for the treatment of pancreatic and triple-negative breast cancer; and RhuDex, which has completed a pilot Phase IIa clinical trial for the oral treatment of autoimmune diseases. It is also developing dendritic cell vaccines that are in Phase II clinical trials for treating prostate cancer; and Phase I/II clinical trials for the treatment of acute myeloid leukaemia. In addition, this segment develops T cell receptor modified T cells, which is in clinical development stage for the treatment of advanced cancer; T cell-specific monoclonal antibodies that is in pre-clinical trial to treat T cell-induced diseases, such as T cell leukaemia or various autoimmune diseases; and adeno-associated virus-like particles, a technology platform for prophylactic and therapeutic vaccines has completed preclinical study. The company was founded in 1994 and is headquartered in Martinsried, Germany.

65 Employees
Last Reported Date: 08/6/15
Founded in 1994

medigene ag (MDGEF) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: €527.0K
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €410.0K
Chief Scientific Officer and Member of Execut...
Total Annual Compensation: €285.0K
Compensation as of Fiscal Year 2014.

medigene ag (MDGEF) Key Developments

MediGene AG Reports Consolidated Earnings Results for the Six Months of 2015; Provides Earnings Guidance for the Fiscal Year 2015

MediGene AG reported consolidated earnings results for the six months of 2015. For the period, the company reported total revenue of EUR 3,372,000 against EUR 6,093,000 a year ago. Operating loss was EUR 4,692,000 against EUR 2,020,000 a year ago. Net loss for the period was EUR 6,113,000 against EUR 2,841,000 a year ago. Negative EBITDA was EUR 4,251,000 against EUR 1,629,000 a year ago. The company confirmed its financial forecast for the fiscal year 2015. The company anticipates an EBITDA loss of EUR 11 million to EUR 13 million. Outside of its core business and based on the assumptions made by the partners, the company expects a double-digit percentage increase in Veregen royalties and stable total revenue for the company. Furthermore, the company expects to generate other operating income consisting mainly of non-cash income from Cowen at a level comparable to the previous year and of reimbursements of development costs for EndoTAG ®-1 from SynCore.

MediGene AG, H1 2015 Earnings Call, Aug 06, 2015

MediGene AG, H1 2015 Earnings Call, Aug 06, 2015

MediGene AG, Annual General Meeting, Aug 13, 2015

MediGene AG, Annual General Meeting, Aug 13, 2015. Location: HannsSeidelStiftung.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDGEF:US $8.27 USD -1.03

MDGEF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $294.89 USD -8.85
Hemispherx Biopharma Inc $0.18 USD -0.0011
Merck & Co Inc $52.59 USD -1.26
View Industry Companies

Industry Analysis


Industry Average

Valuation MDGEF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.8x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIGENE AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at